News >

SM-88 May Fill Unmet Need in Pancreatic Cancer

Brandon Scalea
Published: Monday, Apr 22, 2019

Marcus Smith Noel, MD

Marcus Smith Noel, MD

SM-88, a novel oral compound that is making headway in various solid tumors, has shown early efficacy in patients with metastatic pancreatic cancer. If the regimen continues to be well tolerated, according to Marcus Smith Noel, MD, it may have a place in the third-line setting, which is currently an area of significant unmet need.

We have established first- and second-line agents for pancreatic cancer, but the third-line setting is pretty wide open. SM-88, being a drug that is well tolerated, may fit into the third-line space to hopefully improve survival.
Noel MS, Wang-Gillam A, Ocean AJ, et al. Phase II trial of SM-88 in patients with metastatic pancreatic cancer: preliminary results of the first stage. J Clin Oncol. 2019;37(suppl 4, abstr 200). doi: 10.1200/JCO.2019.37.4_suppl.200.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication